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Abstract
The nuclear-encoded glycyl-tRNA synthetase gene (GARS) is essential for protein translation in both cytoplasm and mito-
chondria. In contrast, different genes encode the mitochondrial and cytosolic forms of most other tRNA synthetases.
Dominant GARS mutations were described in inherited neuropathies, while recessive mutations cause severe childhood-
onset disorders affecting skeletal muscle and heart. The downstream events explaining tissue-specific phenotype–genotype
relations remained unclear. We investigated the mitochondrial function of GARS in human cell lines and in the GarsC210R
mouse model. Human-induced neuronal progenitor cells (iNPCs) carrying dominant and recessive GARS mutations showed
alterations of mitochondrial proteins, which were more prominent in iNPCs with dominant, neuropathy-causing mutations.
Although comparative proteomic analysis of iNPCs showed significant changes in mitochondrial respiratory chain complex
subunits, assembly genes, Krebs cycle enzymes and transport proteins in both recessive and dominant mutations, proteins
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involved in fatty acid oxidation were only altered by recessive mutations causing mitochondrial cardiomyopathy. In contrast,
significant alterations of the vesicle-associated membrane protein-associated protein B (VAPB) and its downstream pathways
such as mitochondrial calcium uptake and autophagy were detected in dominant GARS mutations. The role of VAPB has been
supported by similar results in the GarsC210R mice. Our data suggest that altered mitochondria-associated endoplasmic reticu-
lum (ER) membranes (MAM) may be important disease mechanisms leading to neuropathy in this condition.
Introduction
All genes are copied into short-lived RNA molecules, which are
then translated to proteins, forming the building box of the cells
in the body. Although the majority of protein synthesis happens
in the cytosol, an additional translation apparatus is required to
translate 13 proteins important in mitochondrial energy pro-
duction, which are encoded by the mitochondrial genome (1).
The majority of genes which regulate protein translation in
these cellular compartments are distinct, but two genes encod-
ing aminoacyl-tRNA synthetases of glycine (GARS) and lysine
(KARS) are common, in both mitochondria and the cytosol (2).
Investigating the function of these bi-functional enzymes pro-
vides a unique opportunity to explore interactions between cy-
tosolic and mitochondrial translation and facilitates the
dissection of tissue-specific manifestations of mitochondrial or
cytosolic defects of translation.
GARS encodes the non-redundant homodimeric glycyl-tRNA
synthetase, covalently attaching glycine to its cognate tRNA,
which is essential for the fidelity of protein translation (2).
There are two translation initiation sites resulting in the pro-
duction of mitochondrial and cytoplasmic isoforms of GARS.
Three functional domains are common in both isoforms: a
highly conserved N-terminal WHEP-TRS domain, a catalytic
core and a C-terminal anticodon-binding domain, however a
mitochondrial targeting signal (MTS) is only present in mito-
chondrial GARS (Fig. 1A). Autosomal-dominant GARS mutations
cause axonal CMT (CMT2D) or distal hereditary motor neuropa-
thy with upper limb predominance (dHMN-V) (2). While the ma-
jority of CMT2D mutations were localized to the catalytic
domain, autosomal recessive mutations were reported in three
independent patients with a mitochondrial phenotype (Fig. 1A).
One baby boy, homozygous for c.2065C>T, p.(Arg689Trp), had
severe neonatal cardiomyopathy and cytochrome c oxidase
deficiency and died at 10 days of age (3). Another child
with compound heterozygous c.1904C>T, p.(Ser635Leu) and
c.1787G>A, p.(Arg596Gln) presented with exercise-induced my-
algia, non-compaction cardiomyopathy, periventricular lesions
and increased lactate (4). Recently, recessive mutations within
the catalytic domain were also reported causing multisystem
disease with growth retardation, delayed motor milestones,
dysmorphic signs and complex neurological presentation of mi-
crocephaly, thinning of the corpus callosum, white matter
lesions, cerebellar vermis and brainstem atrophy, but without
peripheral neuropathy (5). To date no neuropathy was
observed in children with recessive mutations however it may
develop later in life. A mild neuropathy was observed on
electrophysiological testing in the heterozygous father of the
second child (4).
Reduced aminoacylation activity, altered axonal localisation
(6,7), impaired catalytic function (8) and more recently the al-
tered neuropilin 1 pathway (9) were described to contribute to
the disease in GARS mutations. However, to date, little is known
about the mitochondrial role of GARS and how it affects the
disease phenotype. Thus, in this study, we explored the
mitochondrial function of the bi-functional enzyme and show
that mutations in GARS lead to tissue-specific mitochondrial de-
fect in neurons with different pathomechanism in autosomal
dominant and recessive mutations.
Results
Patients
We studied cell lines of patients carrying pathogenic GARS
mutations (Fig. 1B and C).
Patient 1 and his mother (II/1) manifested with typical clini-
cal and electrophysiological signs of dHMN-V, both developed
upper limb predominant distal neuropathy since early twenties
(Fig. 1B). They both carry the c.647A>G, p.(His216Arg) mutation
in GARS, detected on a diagnostic multigene next generation
panel. This variant is predicted to be pathogenic based on
Association for Clinical Genetic Science (ACGS) Practice
Guidelines (2013) and segregated with the phenotype in the
family The clinical presentation and family history of patient 2
have been reported previously (4). The 12-year-old girl devel-
oped cardiomyopathy and exercise intolerance at age 6 and car-
ries the compound heterozygous c.1904C>T, p.(Ser635Leu) and
c.178G>A, p.(Arg596Gln) GARS mutations. The mother is hetero-
zygous for the c.1787G>A, p.(Arg596Gln) mutation and shows
no signs of a neuropathy, the father has a mild neuropathy and
carries c.1904C>T, p.(Ser635Leu).
GARS is localized to mitochondrial RNA granules
To prove that GARS is present in the mitochondria and is involved
in mitochondrial translation, we performed double immunofluo-
rescence staining (MitoTracker Red and GARS) in human fibro-
blasts (Fig. 2A–C) and oligodendroglia cells (Fig. 2E–G). GARS was
detectable both in the cytoplasm and mitochondria (Fig. 2A–L) and
was present in mitochondrial RNA granules (Fig. 2M and N), which
was confirmed using multiple markers including Mitotracker,
MTCO1 and GRSF1, respectively. GARS-associated aggregates in
fibroblasts were previously reported (10). These cytoplasmic gran-
ules labelled with eIF4E representing processing bodies (PB) or
stress granules (SG) did not confirm co-localization (Fig. 2O and P).
These results show that GARS is present in RNA granules in mito-
chondria, thus may affect mitochondrial translation.
siRNA down-regulation of GARS results in abnormal
mitochondrial translation in myoblasts and
oligodendroglia
We first tested in vitro whether mitochondrial protein synthesis
in fibroblasts is altered by any of these variants. None of the
fibroblasts from these patients showed a mitochondrial transla-
tion defect, which is not uncommon in mitochondrial diseases
with tissue-specific clinical presentations. Next we performed
siRNA-mediated downregulation of GARS with two different
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siRNAs in normal human fibroblasts, myoblasts and also in
SHSY-5Y cells, providing the most relevant cellular model of
GARS-related disease. We detected significantly decreased
protein levels of respiratory chain subunits in myoblasts
(Fig. 2Q and S) and SHSY-5Y cells (Fig. 2Q and T), but not in
fibroblasts (Fig. 2Q and R), which is illustrating that loss of
function of GARS result in a tissue-specific mitochondrial
translation defect. Both siRNAs successfully down-regulated
GARS in all cell types both in the cytosol and mitochondria
(data not shown).
Figure 1. Schematic representation of the GARS protein and distribution of dHMN-V and mitochondrial disease-associated dominant and recessive mutations.
(A) Dominant mutations causing CMT2D/dHMN-V are mostly located in the catalytic domain marked with black. Recessive mutations leading to mitochondrial disease
localized in the catalytic domain and at the anticodon binding domain (ACBD) shown by the black arrows. Mutations modelled in this study are highlighted with red,
orange, green and purple. (B) Pedigree of patient 1 with a novel heterozygous c.647A>G, p.(His216Arg) mutation, both patient 1 and his affected mother show promi-
nent atrophy of small hand muscles and moderate atrophy and weakness in the feet. (C) Summary of the clinical presentations of the patients (patient 1 and 2) and
heterozygous parents of patient 2 (carrier 1 and 2) whose fibroblasts were used in this study.
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Figure 2. Endogenous GARS downregulation in human cells. (A) Human control fibroblasts and (E, I) MO3.13 cells were immunostained for GARS (green) and mitochon-
dria (Mitotracker, red) (B, F, J). Merged images are shown in (C, G, K). White lines indicates the location of the XY slice. Representative XY sections show co-localization
of GARS with mitochondria (Mitotracker) in fibroblasts (D) MO3.13 cells (H) and GARS-MTCO1 (red) co-localization in MO3.13 cells (L). Staining for the mitochondrial
2190 | Human Molecular Genetics, 2018, Vol. 27, No. 12
D
ow
nloaded from
 https://academ
ic.oup.com
/hm
g/article-abstract/27/12/2187/4966856 by U
niversity of N
ew
castle user on 22 O
ctober 2018
Reduced mitochondrial respiratory chain enzymes in
induced neuronal progenitor cells (iNPCs) of patients
carrying dominant and recessive GARSmutations
Based on the neuron-specific manifestations in patients, we
studied neuronal cell lines. We took advantage of a recently de-
veloped method converting human fibroblasts directly into
iNPCs to model neurodegenerative disorders (11). Within one
week of conversion, the expected change in morphology was
observed (Fig. 3A) and efficient viral transduction was confirmed
by quantitative RT-PCR (Supplementary Material, Fig. S1A–D).
Primary fibroblasts from two patients, two GARS mutation car-
riers and two healthy controls were converted (Fig. 3B) and RT-
PCR (Fig. 3B–D), immunofluorescence staining (Fig. 3E) and west-
ern blot (Fig. 3F) for fibroblast and iNPC markers revealed suc-
cessful down-regulation of fibroblast markers and strong
upregulation of iNPC markers in all cell lines (Supplementary
Material, Fig. S1E).
RNA sequencing (RNAseq) in induced neuronal
progenitor cells (iNPCs) of patients 1 and 2
To further address the conversion toward neuronal cell linage,
RNA isolated from control fibroblasts and control and patient
iNPC cells, was subjected to RNAseq analysis. The iNPC cell
lines of patient 1, patient 2 as well as a control iNPC line were
clearly grouped together in a hierarchical clustering of the RNA
read count sample distance matrix (Fig. 4A). This indicates that
the iNPCs are not related to fibroblasts and they are likely to ex-
hibit a functionally distinct and unique transcriptome.
Examination of the log 2 fold change in control iNPC versus con-
trol fibroblast RNAseq read counts revealed that thousands of
genes exhibited a significant difference in expression between
the fibroblast and iNPC lines (Fig. 4B). This included differential
expression of genes involved in neuronal function. GO terms
that were significantly enriched for genes showing significant
up-/down-regulation of RNA expression in both patient iNPCs
lines versus control iNPCs are represented in Figure 4C, com-
pared with the distinct lists of the most significantly enriched
GO terms, specific to each patient shown in Supplementary
Material, Figure S2A and B. In further support of the neuronal
fate in our iNPCs neuronal markers NES, CD24, ROR2, FZD3,
USP44 are significantly overexpressed in iNPCs compared with
fibroblasts and we detected SOX2 expression, which is not pre-
sent at all in fibroblasts. These neuronal markers have been pre-
viously reported as specific for neuronal stem cells and provide
evidence of a neuronal fate in our iNPCs (12). We could not de-
tect significant changes in mRNA expression of genes of mito-
chondrial proteins which showed significant changes in the
proteomic data, therefore we suggest that the changes occur on
the protein level, which is in line with the defect in protein
translation and altering protein–protein interactions.
After confirming the successful conversion of the cell lines,
we measured mitochondrial function in iNPCs. The number of
mitochondria and the copy number of mtDNA gradually in-
creased in iNPCs and the defect became more pronounced after
eight passages, confirming the higher energy demand in neuro-
nal cells (Supplementary Material, Fig. S3A). While no defect
was observed in fibroblasts (Fig. 5A and B, E and F), we detected
significantly decreased level of the complex I subunit NDUFB8
in patient 2 and the mildly affected father (carrier 2), while a mi-
tochondrial encoded complex IV subunit (MTCO1) was signifi-
cantly reduced in iNPCs of patient 1 (Fig. 5C and D).
Mitochondrial proteins remained normal in control iNPCs and
in the healthy mother (carrier 1) carrying the heterozygous
p.(Arg596Gln).
BN-PAGE showed significantly lower levels of all five mito-
chondrial complexes in iNPCs of patient 1, but no defect was ob-
served in any of the other iNPC lines (Fig. 5G and H) or in
fibroblasts (Fig. 5E and F). Interestingly, mitochondrial GARS
was increased in symptomatic patients’ fibroblasts, suggesting
compensation, possible through redistribution (as seen in
mice), while in iNPCs from all patients and carriers, the amount
of GARS was consistently lower in both mitochondria and cyto-
sol (Supplementary Material, Fig. S3B–E). Immunofluorescent
staining confirmed lower expression of respiratory chain subu-
nits of complexes I and IV (NDUFS2, MTCO2) in iNPCs of all
symptomatic individuals (Fig. 6) raising the possibility that the
mitochondrial translation defect may be caused by the loss of
function of GARS in neurons.
MitoTracker Red CMXRos accumulates only in actively re-
spiring mitochondria that have an intact membrane potential
(DWm) (13). A deficient MitoTracker Red staining and the less
elongated appearance of mitochondrial networks in iNPCs de-
rived from patient 1 suggest that DWm is altered in these cell
lines (Fig. 6).
Mitochondrial respiration measured on Seahorse XF96
showed that all fibroblasts from affected individuals with differ-
ent GARS mutations had slightly higher maximal respiration
than controls, suggesting compensation, while there was no dif-
ference in basal respiration and proton leak (Fig. 7A–D).
However, we detected significantly reduced respiration in iNPCs
of patient 1 (Fig. 7A–D). Additional analysis of iNPCs of patient 1
revealed increased oxidative stress (CellROXVR Green staining)
(Fig. 6E and F).
In summary, we detected a neuron-specific defect of mito-
chondrial proteins in iNPCs of patient 1, which correlated with
the neuropathy.
Comparative mitochondrial proteomics identified
different alterations in iNPCs of patients with dominant
and recessive GARSmutations
Comparative proteome profiling in iNPCs of patient 1 (domi-
nant) and patient 2 (recessive) identified significant changes in
several mitochondrial proteins when compared with control
iNPCs. A detailed analysis of cellular processes influenced by
these proteins was performed using STRING (Search Tool for
RNA granule marker GRFS1 (red) and GARS (green) in fibroblasts (M). Boxed area is shown as zoomed image (N). Staining for cytosolic RNA granule marker eIF4E (red)
and GARS (green) in fibroblasts (O). Boxed area is shown as zoomed image (Q). Human fibroblasts, myoblasts and SHSY-5Y cells were subjected to siRNA mediated
GARS downregulation. Cells were transfected with non-targeting (NT) siRNA, and two different GARS siRNAs (GARS siRNA 1 and 2) for 9 days. After 9 days of treatment
total cell lysates were collected from the cells. The silencing of GARS protein and the steady-state level of mitochondrial proteins were determined by western blots.
GAPDH was used as loading control (R, S, T). Bar graph indicates the level of mitochondrial proteins in un-transfected (control), NT siRNA transfected and GARS siRNA
treated fibroblasts (R), myoblast (S) and SHSY-5Y cells (T). Error bars show standard deviation. Three independent experiments were performed. One-way ANOVA fol-
lowed by Bonferroni post-hoc test (with 97% confidence intervals) were used in comparing the level of protein expression (*P < 0.5 versus cont. and non-targeted
samples).
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Figure 3. Characterization of iNPCs. (A) Phase-contrast images show the conversion process from the initial fibroblasts to iNPC cultures. Morphological changes were appar-
ent after 7 days of transfection. Cells began to form sphere-like structures at 21 days. Scale bars, 50 mm. iNPCs and primary fibroblasts were collected and subjected to total
RNA extraction and real-time PCR analysis. (B, C) iNPC markers (Nestin, Mushashi-1, Noggin, Ncan and Nkx2-2) demonstrated significantly higher expression levels, sug-
gesting neuronal fate, and (D) reduced expression of fibroblast markers (Dkk1, Twist2, Col1a1 and Snail1) indicated loss of fibroblast characteristics (n ¼ 3 independent ex-
periment). Error bars represent standard deviation. (E) Immunofluorescence staining of fibroblasts and iNPC cultures at day 20 reveals loss of Collagen I (fibroblast marker)
and increased expression of the iNPC markers Nestin and SB100 in the iNPCs (bottom row). DAPI was used to visualise nuclei. Scale bars, 20 mm. (F) Protein levels of iNPC
marker proteins (Tuj-1, Notch1, NF66, PAX6) demonstrated higher levels in the iNPCs confirming the neuronal fate. GAPDH was used as loading control.
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the Retrieval of Interacting Proteins) software (version 10.0). The
protein–protein interactions between the altered proteins ana-
lysed by STRING is shown in Figure 8A and B. We observed>2
times different abundance in both patients’ iNPCs of subunits
and assembly factors of respiratory chain enzyme complexes,
Krebs cycle enzymes and proteins involved in mitochondrial
transport. Significant alterations of fatty acid oxidation proteins
were only observed in the mitochondrial patient’s iNPCs
(Fig. 8A). VAPB and proteins acting downstream from VAPB
were significantly down-regulated only in iNPCs of patient 1
(Fig. 8B). VAPB binds to protein tyrosine phosphatase interacting
protein 51 (PTPIP51), and is known to be involved in connecting
ER with mitochondria as part of the mitochondria-associated ER
membranes (MAM) complex (14). Based on the differentially
expressed proteins we identified several biological processes
different in the mitochondrial or neuropathy cell lines
(Supplementary Material, Table S1).
Mitochondrial calcium uptake was significantly altered
in fibroblasts and iNPCs of patients carrying pathogenic
GARSmutations
To confirm the altered expression of VAPB in patient cells we
performed immunoblotting for VAPB and its interacting part-
ner PTPIP51 in both fibroblasts and iNPC cells (Fig. 9A and B).
Our data indicated significantly reduced levels of VAPB and
PTPIP51 in the cells of patient 1, and more importantly the lack
of VAPB protein was more evident in the iNPCs compared to
fibroblasts (Fig. 9B).
The primary role of MAM is to facilitate delivery of Ca2þ to the
mitochondrial matrix from ER stores. Thus, reduced levels of VAPB
loosen the ER-mitochondrial associations and perturb this deliv-
ery. To address the possible role of GARS in mitochondrial Ca2þ ho-
meostasis we monitored the mitochondrial Ca2þ uptake following
its release, induced by histamine, from ER stores. For these experi-
ments we used both fibroblasts and iNPCs cells. After recording
the baseline where indicated (Fig. 9E and G), cells were exposed to
100 lM histamine (His), causing the generation of inositol 1, 4, 5 tri-
sphosphate (InsP3) and the consequent opening of the InsP3 chan-
nels of the intracellular stores. Representative traces of typical
experiments for fibroblasts and iNPCs are shown in Figure 9E and
G. Mitochondrial Ca2þ influx in cells of patient 1 were significantly
lower in both cell types than those observed in control or cells of
patient 2. Peak values are shown in Figure 9F and H.
To complement these studies, we also analysed the autophagy
in the iNPC cells. Recently published work showed that the VAPB-
PTPIP51 tethers regulate autophagy by mediating the delivery of
Ca2þ to the mitochondria from the ER stores (15). Autophagy detec-
tion kit was used specifically label autophagosomes (Fig. 9I). Fully
in line with our findings we identified significantly enlarged and
increased numbers of autophagic vacuoles in the neuropathy cell
line compared with control cells (Fig. 9J and K).
Investigations in the GarsC210Rmice detected significant
changes in MAM proteins and mitochondrial
dysfunction in sciatic nerve
To investigate the effect of GARS mutations on mitochondrial
translation and on MAM proteins we studied different tissues in
GarsC201R mice. Homozygous GarsC201R/C201R mice have severe
motor deficits and die between 14 and 17 days. Heterozygous
GarsC201R/WT mice present with a reduction in axon diameters and
muscle weakness at 3 months of age (16). First we studied
Figure 4. RNAseq analysis of patient and control iNPS, and control fibroblasts.
(A) Heat map showing hierarchical clustering of the RNAseq read count sample dis-
tance matrix demonstrating the dissimilarity between the RNA sequencing expres-
sion profiles of the control fibroblasts versus the iNPCs (control and patient) (B)
Volcano plot of log10 adjusted P-value versus the log 2 fold change in RNA expres-
sion of iNPCs cells compared to fibroblasts, again demonstrating the large number of
RNAs showing differential expression between the iNPCs and fibroblasts. (C) Word
Cloud of GO terms that were significantly enriched for genes showing significant
up-/down-regulation of RNAs in both patients’ iNPC cells versus control iNPC cells.
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mitochondrial protein synthesis by 35S methionine pulse-labelling
in primary fibroblasts isolated from wild-type, heterozygous and
homozygous mice. Our data, using Coomassie blue stained gel as
loading control, showed normal result (Supplementary Material,
Fig. S6). We could not detect a mitochondrial translation defect in
mouse fibroblasts, similar to our data in patient fibroblasts.
Next, we investigated the expression level of VAPB and
PTPIP51 in isolated sciatic nerve at P7. We detected significantly
Figure 5. Mitochondrial protein expression and level of RC enzymes in fibroblasts and iNPCs. (A, C) Western blot analysis of fibroblast and iNPCs cell lines: two controls
(C1, C2), patient 1, patient 2, carrier 1 (asymptomatic mother) and carrier 2 (father with mild neuropathy). Immunoblotting detected the expression of mitochondrial
proteins. GAPDH was used as loading control. (E–G) BN-PAGE analysis studied the assembly and level of RC enzymes in fibroblasts (E) and iNPC cells (G). Porin was used
as loading control. (B, D, F, H) Quantification of the levels of mitochondrial proteins and individual OXPHOS complexes were normalized to GAPDH and porin levels re-
spectively. Bar graphs representing the relative mitochondrial protein expression were analysed with unpaired t-test on Sigma plot (version 11.0) where samples repre-
sent n ¼ 3 (experimental replicates), P-values are from paired t-test: *P < 0.05. Bar graphs represents the mean 6 standard deviation *P < 0.05.
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reduced levels of VAPB and its interacting partner PTPIP51 in
homozygous GarsC201R/C201R mice while no changes were found
in heterozygous GarsC201R/WT mice (Fig. 10A, D and E).
Furthermore, detection of GARS protein revealed a complete
lack of gars dimers in GarsC201R/C201R animals which are the ac-
tive form of the enzyme [Fig. 10A (upper band) and B]. On the
other hand the level of GARS monomer was unaltered com-
pared to wild-type littermates [Fig. 10A (lower band) and C].
Figure 6. Immunostaining of mitochondrial proteins in human fibroblasts and iNPCs. Representative fluorescent images of mitotracker (black and white), MTCO2
(green channel) and NDUFS2 (red channel). Abnormal MitoTracker staining indicates abnormal mitochondrial membrane potential in patient derived iNPCs (marked
with white star). iNPCs with GARS mutations in patient 1, patient 2 and carrier 2 show weak signals of mitochondrial proteins (indicated with white arrows) confirming
mitochondrial translation defect (scale bar represents 20 um).
2195Human Molecular Genetics, 2018, Vol. 27, No. 12 |
D
ow
nloaded from
 https://academ
ic.oup.com
/hm
g/article-abstract/27/12/2187/4966856 by U
niversity of N
ew
castle user on 22 O
ctober 2018
Based on our human iNPCs data indicating mitochondrial
defect in patients, we also studied the level of mitochondrial
proteins in different mouse tissues. The amount of mitochon-
dria detected by porin expression suggested significant decrease
(Fig. 10A and F) in the sciatic nerve of the GarsC201R/C201R animals
and we detected significantly lower level of complex I, IV and V
subunits (Fig. 10G and H). Other highly metabolic tissues were
also analysed (skeletal muscle, brain, heart, liver and kidney) at
P0 and P14. The expression level of mitochondrial respiratory
chain complexes were normal in all mice (Supplementary
Material, Figs S4A–D and S5A–D) at both time points, and only a
mild, not significant decrease of complex I was detected in skel-
etal muscle of both heterozygous and homozygous mice
(Supplementary Material, Fig. S5E) at P14. Measurements of en-
zyme activities also showed normal levels in these tissues
(Supplementary Material, Figs S1F–I and S2F–I).
In summary, extensive investigations in the GarsC210R mice
detected tissue-specific mitochondrial dysfunction and altered
level of MAM proteins in sciatic nerve only, while all other tis-
sues showed normal results.
Figure 7. Mitochondrial functional studies. Oxygen consumption levels were monitored using the Seahorse Bioscience ExtraCellular Flux Analyser in real time. OCR is
indicative of OXPHOS. Basal respiration, proton leak and maximal respiration of fibroblasts (A) and iNPCs are shown (B). Values were calculated from the mean values
of each real-time run normalized to the protein concentration (n ¼ 3). Oxygen consumption data are presented as 6 standard deviation using two-way ANOVA test
on Sigma plot (version 11.0) and paired t-test. A P-value of 0.05 was considered significant. The P-values are from an unpaired t-test. Where indicated *P < 0.05.
(C, D) Real-time effect of control and patient 1 cells (GARSHis216Arg) is demonstrated on OCR in fibroblasts and in iNPCs. (E, F) Fluorescent micrographs of control and
fibroblasts and iNPCs of patient 1 show intracellular ROS formation as stained by the CellRox Green Reagent. Light green fluorescence indicates increased levels of oxi-
dative stress in H2O2-treated cells as positive controls and in iNPCs of patient 1. DAPI shows nuclei. Scale bar ¼ 20 lm.
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Discussion
It has been shown in mice that mutant GARS acquires a neo-
morphic binding activity to neuropilin 1 (Nrp1) receptors that
directly antagonizes an essential signalling pathway for motor
neuron survival (9). This aberrant interaction interferes with the
binding of the vascular endothelial growth factor (VEGF) to
Nrp1. Genetic reduction of Nrp1 in mice worsens neuropathy,
whereas enhanced expression of VEGF improves motor func-
tion. It seems to be an important pathomechanism of the se-
creted GARS outside the neurons however it does not explain all
abnormalities observed in GARS mutations.
In this study we identified that reduction or loss of GARS (by
siRNA down-regulation or some pathogenic mutations) result in
decreased translation of mtDNA and nuclear encoded subunits
confirming that GARS is important for obtaining mitochondrial
Figure 8. Differentially regulated mitochondrial proteins identified in patient iNPCs. Comparative proteomic analysis of mitochondrial proteins was performed on three
iNPC cells lines (patient 1, patient 2 and control). A total of 85 differentially expressed mitochondrial proteins were identified in comparison between control and pa-
tient groups. Screen shot of the STRING (Search Tool for the Retrieval of Interacting Proteins) showed a network of differentially expressed proteins in cells of patient 2
(A) and patient 1. (B) Black circles indicated protein clusters directly affecting mitochondrial function. Red circles represent protein clusters related to vesicle-associ-
ated membrane proteins and its downstream pathways. Blue circle represents fatty acid oxidation pathway. The interactions are shown in confidence view. Thicker
lines represent a stronger association. The proteins are identified by their gene names located near each sphere.
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Figure 9. Western blot analysis and Ca2þ measurement in control and patient cell lines. (A, B). Total protein lysate from control and patient fibroblasts and iNPCs cells
were analysed by immunoblotting using VAPB, PTPIP51, GAPDH and GARS antibodies. Representative blots from three independent experiments are shown. (C, D) Bars
represent the average protein expression levels normalized to GAPDH obtained by densitometry analysis. Error bars show standard deviation, **P < 0.005, *P < 0.05.
Data were analysed with paired t-test on Sigma plot (version 11.0) where samples represents n ¼ 3 (experimental replicates). Mitochondrial Ca2þ transients in fibro-
blasts (E) and iNPCS cells (G) are shown. Mitochondrial Ca2þ transients were induced by cell stimulation with 100 lM histamine. The traces are representative of at least
10 independent experiments. Bars indicate the average heights of peak values (F, H). Results are the mean 6 Standard deviation *P < 0.05. Data were analysed with
unpaired t-test on Sigma plot (version 11.0) where samples represent n ¼ 10 (experimental replicates). The P-values are from an unpaired t-test, *P < 0.05. Cell line of pa-
tient 1 harbouring the dominant GARS mutation increased the number and size of the autophagic structures. Representative images of cells are shown with DAPI-
labelled nuclei. Scale bars are 10 um (I). Bar charts show quantification of autophagosomes (dots/cell) (J) and average size of the autophagic structures (K). n ¼ 30–50
cells per condition in three independent experiments. Data were analysed by one-way ANOVA and Dunn’s method. Error bars are standard deviation *P < 0.05.
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Figure 10. Investigations of mitochondrial function in different tissues of the GarsC210R mouse. (A) Western blot shows the level of MAM proteins and mitochondrial
subunits in wild type, GarsC201R/wt and GasrC201R/C201R mouse sciatic nerve. Sciatic nerves were isolated at P7 and equal amounts of protein were analysed. Actin was
used as a loading control for total cell lysates. (B–F) Graphed data are presented as mean (6 SD) from three separate experiments. Data were analysed with unpaired
t-test on Sigma plot (version 11.0) where samples represents n ¼ 6. (G) Immunoblotting for subunits of mitochondrial complexes. Total tissue lysate isolated from
sciatic nerve of wild-type (WT), heterozygous (GarsC201R/WT) and homozygous (GarsC201R/C201R) animals at P7. Mouse tissues were incubated with different antibodies CI
subunit (NDUFA9), CII subunit (SDHA), CIII (UQCRC2), CIV subunit (COX IV) and CV subunit (ATP5A). Actin was used a loading control. (H) Densitometry of western
blotting was performed using ImageJ software. Data in arbitrary units (a.u.) represent the mean 6 SD of three separate experiments (n ¼ 6). Data were analysed with
unpaired t-test on Sigma plot (version 11.0), *P < 0.05 compared with WT samples.
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function, and that loss of function of GARS result is reduced
mitochondrial translation. We showed that siRNA down-
regulation of GARS resulted in reduced mitochondrial transla-
tion in neuronal cells and myoblasts, but not in fibroblasts, sug-
gesting that GARS mutations may lead to a tissue-specific
mitochondrial translation defect due to loss of function. We
could not demonstrate a defect of mitochondrial protein syn-
thesis in a mouse model of GARS (GarsC201R) in five different tis-
sues. The steady-state level of Gars was not altered by the
mutation, and we detected redistribution of Gars into mito-
chondria, which may have prevented respiratory chain dys-
function, as higher protein levels of Gars were detected in
mitochondria in the studied tissues.
Furthermore, we detected complex alterations of mitochon-
drial metabolism, which cannot be fully explained by a defect of
cytosolic and mitochondrial translation suggesting that GARS
has other non-canonical functions within neurons (17,18). The
canonical role of GARS would be the addition of glycine residues
to the cognate tRNA during mitochondrial and cytosolic protein
translation and we focussed on studying mitochondrial transla-
tion. We detected partial co-localization of GARS with mito-
chondrial RNA granules. Mitochondrial RNA granules are the
centres of posttranscriptional RNA processing and the biogene-
sis of mitochondrial ribosomes (18) and provide a platform for
the spatiotemporal regulation of numerous processes including
RNA maturation, ribosome assembly and translation initiation
(19), supporting the role of GARS in mitochondrial translation
and raising the possibility that mutant GARS may cause alter-
ation of these functions. However mitochondrial RNA granules
are not specific for neurons and do not explain the tissue specif-
icity in the pathomechanism of GARS mutations.
We generated iNPCs by direct conversion from human fibro-
blasts and show that this is an excellent cellular model to study
tissue-specific mechanisms in neurons. We detected an abnor-
mal translation of mtDNA and nuclear-encoded mitochondrial
proteins and abnormal mitochondrial respiration in neuronal
cells, but not in fibroblasts of patients compared with controls.
Interestingly, these changes were more prominent in iNPCs of
the dHMN-V patient carrying a dominant, probably gain-of-
function GARS mutation (patient 1), suggesting that some
neuropathy-associated mutations result in more severe or com-
plex alteration of mitochondrial function in neurons.
We further investigated the mitochondrial defect by RNAseq
and by comparative proteomics in iNPCs carrying autosomal
dominant and recessive GARS mutations which showed several
significant changes of the mitochondrial transcriptome and
proteome. Altered levels of mitochondrial respiratory chain
subunits, Krebs cycle enzymes and proteins involved in mito-
chondrial transport and respiratory chain assembly were
detected in both mutant iNPCs. In addition, significant changes
were identified in the fatty acid metabolism only in iNPCs with
recessive GARS mutations (Fig. 8A). In support of the relevance
of these findings, exercise intolerance, myopathy and cardiomy-
opathy, typically present in defects of fatty acid oxidation, were
observed in the patients reported to date with recessive GARS
mutations (20).
iNPCs carrying a neuropathy-related dominant GARS muta-
tion showed reduced VAPB and its downstream pathways, in-
cluding altered mitochondrial and cellular calcium
homeostasis, providing a potential explanation for neuron-spe-
cific clinical manifestations (Fig. 8B). Autosomal dominant
mutations in VAPB were reported in several families world-wide
with clinical presentations of ALS (ALS8) or distal spinal muscu-
lar atrophy (14,21). VAPB is part of the mitochondria-associated
ER membrane (MAM) complex and was shown to bind to the
outer mitochondrial membrane protein PTPIP51 to tether ER to
mitochondria and plays an important role in the quality control
and provides an additional level of flexibility of neurons to cope
with misfolded protein stress in the ER (22). Modulating VAPB
induces changes in ER-mitochondria contacts and Ca2þ ex-
change between the two organelles, and predicted to lower
mitochondrial ATP production (22). It has been very recently
shown that the VAPB-PTPIP51 tethers regulate autophagy through
mediating delivery of Ca2þ to mitochondria from ER stores, pro-
viding a new molecular mechanism for regulating autophagy (15).
In support of the relevance of reduced VAPB, we also detected low
protein levels of its direct interacting partner PTPIP51 and several
proteins involved in pathways downstream of VAPB were altered
including calcium metabolism, ubiquitination, ephrin signalling,
ER trafficking and vesicle fusion (SNARE) (Fig. 8B).
In support of the functional effect of reduced VAPB, we
detected a significant defect of mitochondrial calcium metabo-
lism in fibroblasts and neuronal cells in the dHMN-V patient
(patient 1). Furthermore, significant increase of autophagy was
observed in the patient cells (Fig. 9I and J) and the average size
of autophagic structures was significantly increased specifically
in patient 1 (Fig. 9K). Furthermore, extensive investigations in
the GarsC210R mice detected tissue-specific mitochondrial dys-
function and altered level of MAM proteins in sciatic nerve only,
while all other tissues showed normal results. Based on the re-
duced level of MAM proteins and respiratory chain subunits we
think that the homozygous p.Cys201Arg mutation has a loss-of-
function effect in GarsC201R mice, while we cannot provide ex-
perimental evidence of the loss of function in the heterozygous
animals.
Although further studies are needed to explore the exact
mechanism of the GARS/VAPB connection we suggest that mu-
tant GARS has an impact on mitochondrial calcium metabolism
and ER–mitochondria interactions which contribute to the neu-
ron-specific clinical presentations. Furthermore, the changes
detected in our study may provide a functional link between the
previously identified presynaptic defects of neuromuscular trans-
mission and GARS mutations, as calcium signalling is important
for vesicle refinement at the neuromuscular junction (23).
The importance of MAM in motor neurons has been
highlighted by the fact, that mitofusin 2 (MFN2), a common
cause of axonal CMT (CMT2), has been suggested to act as an
ER-mitochondria tether, and its ablation decreases interorga-
nellar communication (24). Many functions regulated by ER–mi-
tochondria associations have been shown to contribute to
neurodegenerative diseases such as amyotrophic lateral sclero-
sis/frontotemporal dementia (ALS/FTD), Alzheimer’s disease
(AD) and Parkinson’s disease (PD), however the exact mecha-
nism involved in damage of different neuronal cell types in
these diseases needs further investigations. Here we show that
the ER-mitochondria axis is altered in GARS-related neuropa-
thy, highlighting that MAM is particularly important in motor
neurons.
In summary, we show that a different type of mitochondrial
dysfunction underlies autosomal recessive and dominant GARS
mutations. While a defect of mitochondrial protein synthesis in
recessive GARS-related mitochondrial disease is most likely a
result of loss of function, in dominant neuropathy-causing
mutations we identified a defect of the MAM complex, suggest-
ing that mitochondria ER interactions and calcium metabolism,
possible due to non-cognate function of GARS may potentially
explain tissue-specific clinical manifestations in human motor
neurons.
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Materials and Methods
Cell culture
Cultured myoblasts were grown in skeletal muscle cell growth
medium and supplement mix (PromoCell) supplemented with
10% (v/v) foetal bovine serum (FBS, Sigma Aldrich) and 4-mM L-
glutamine (Invitrogen) and cultured as recommended by the
supplier. Fibroblasts were grown in high glucose Dulbecco’s
modified Eagle’s medium (DMEM, Sigma, Poole, UK) supple-
mented with 10% FBS. Myoblasts cell line was immortalized by
transduction with a retroviral vector expressing the catalytic
component of human telomerase (25). Human oligodendrocyte
cells (MO3.13) and a human bone marrow neuroblastoma cell
line (SHSY-5Y) were grown in DMEM: F12 supplemented with
10% FBS. The human oligodendroglia cell line was a kind gift of
Dr. Josephine Nalbantoglu from the McGill University, where it
was originally characterized.
Conversion of skin fibroblasts to iNPCs
The method used was described previously in Meyer et al. (11).
siRNA-mediated down-regulation
Silencer GARS siRNA (number siRNA, Ambion–Life Technologies)
was transiently transfected in control myoblasts, fibroblasts and
in SHSY-5Y human neuroblastoma cell line at a final concentra-
tion of 20 nM using Lipofectamine RNAiMAX (Invitrogen), accord-
ing to the manufacturer’s specifications. Transfections were
repeated on day 3 and day 6, cells were harvested on day 9. A
non-targeting SilencerSelect Negative Control (#1) was used as a
control.
BN PAGE, in-gel activity and immunoblotting
About 3% and 15% gradient gels and a 4% stacking gel were pre-
pared for BN PAGE according to the protocol of Calvaruso et al.
(26). A Gilson MiniPuls 3 gradient gel mixer (Gilson, USA) was
used at a speed of 5.38 ml/min. SBG buffer [750 mM aminocap-
roic acid, 5% Coomassie Brilliant Blue G250 (Biorad, UK)) was
added to the samples and 2 lg of each sample used. Following
electrophoresis the gel was transferred to a PVDF membrane,
de-stained, blocked and incubated with primary antibody to
the respiratory chain complexes (complex I subunit NDUFA9—2
lg/ml, complex II 70 kDa subunit—0.2 lg/ml, complex III core 1
subunit—1 lg/ml, complex IV subunit 4–1 lg/ml, complex V ATP
synthase—0.25 lg/ml, all Abcam, UK), a secondary rabbit anti-
mouse antibody (Dako, UK) (0.5 ll per ml) and then developed
with ThermoScientific Pierce ECL2 Western Blotting kit or
BioRad Clarity Western ECL Solution. The signal was detected
with the UVP BioSpectrum 500 Imaging System and the inten-
sity quantified using Image J software. ‘In-gel’ assays were car-
ried out as described (27).
Pulse-labelling of mitochondrial translation products
In vivo 35S-metabolic labelling studies were performed as de-
scribed previously with the following modifications. Cells, cul-
tured to 60–70% confluency in T25 mm flasks, washed with
phosphate-buffered saline (PBS; Sigma) and washed by incubat-
ing twice for 10 min at 37C/5% CO2 in methionine/cysteine-free
DMEM (Sigma, Poole, UK), with the media replaced between
each incubation. Cells were then incubated for 15 min at
37C/5% CO2 in methionine/cysteine-free DMEM supplemented
with 5% (v/v) dialyzed FBS, 0.1 mg/ml emetine dihydrochloride
(Sigma). Following addition of 200 mCi/ml 35S-methionine/cys-
teine (35S EasyTag EXPRESS; Perkin Elmer), cells were incubated
for 15 min at 37C/5% CO2, then washed twice with ice-cold
DMEM supplemented with 7.5 mg/ml methionine. Cell pellets
were prepared after washing once with ice-cold PBS. Radio-
labelled proteins were then analysed using SDS–PAGE as de-
scribed previously.
Mitochondrial extraction frommouse tissues
Unless specified all chemicals were purchased from Sigma (Sigma
Aldrich, UK). Liver, brain kidney heart and muscle tissue was
weighed and added to a glass Elvehjem potter with 10 volumes of
Buffer A (0.32 M sucrose, 10 mM Tris–HCl and 1 mM EDTA) to the
weight of tissue. The homogenate was then centrifuged at 1000g
for 5 min. The remaining supernatant was centrifuged at 9000g for
10 min and the pellet re-suspended in 100 ll Buffer A with digito-
nin (1 in 200 of weight of tissue). Protease inhibitor tablet (Sigma)
in 10 ml PBS (PI/PBS) was added to dilute the digitonin and the
sample was centrifuged at 10 000g for 10 min. The pellet was re-
suspended in 30–100 ll of MB2 buffer [0.5 ml 3 gel buffer (1.5 M
aminocaproic acid, 150 mM Bis–Tris, pH 7), 0.5 ml 2 M aminocap-
roic acid, 4 ll 500 mM EDTA) depending on its size. N-dodecyl B-D-
maltoside in PI/PBS was added to a final concentration of 1%, vor-
texed, incubated on ice for 15 min and then centrifuged at 16 000g
for 30 min. The supernatant was removed and saved.
Gene expression studies
cDNA was generated by reverse transcription of 500 ng of total
RNA using the Superscript VILO cDNA synthesis kit (Invitrogen,
11754-050) according to manufacturers’ instructions. qPCR
(Applied Biosystems 7900HT) was performed in triplicate on
cDNA using SYBR Green PCR Master Mix (Invitrogen, 4309155).
Samples were normalized using the average of two reference
genes, GAPDH and actin. Primers are shown in Supplementary
Material, Table S2.
Immunofluorescence
Cells were fixed with 4% paraformaldehyde for 15 min and
washed 3with Tris-buffered saline (TBS) before the blocking
solution consisting of TBS with 10% donkey serum, 0.1% Triton
X-100 and 0.1% Tween-20 was applied for 1 h. All primary anti-
bodies were diluted in blocking solution (MTCO2, Abcam;
MTCO1, Abcam; NDUFS8, Abcam; NDUFS2, Abcam; GARS,
Proteintech; S-100Beta, Abcam; Collagen 1, Abcam; Nestin,
Milliopore; GRFS1, Abcam; eIF4E, Abcam; Mitotracker,
Invitrogen). Incubation of the primary antibody was performed
overnight at 4C. The next day, cells were washed 3 in TBS be-
fore the secondary antibody (Alexa-Fluor Anti-Rabbit 488,
Alexa-Fluor Anti-mouse 594, Invitrogen) and DAPI diluted in
blocking solution was applied for 1.5 h at room temperature.
Immunofluorescence images were collected using a Zeiss Axio
Imager Z1 fluorescence microscope equipped with Zeiss
Apotome 2 (Zeiss, Germany) in AxioVisionRel 4.9 software.
Oxygen consumption measurement
Oxygen consumption was measured in adherent fibroblasts and
iNPCs with a XF96 Extracellular Flux Analyzer (Seahorse
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Bioscience Billerica, MA, USA) as described earlier (28). Each cell
line was seeded in 12 wells of a XF96-well cell culture micro-
plate (Seahorse Bioscience) at a density 30  103 cells/well (20 
103 cells/well for iNPCs) in 80 ul of DMEM and incubated for 24
h at 37C in 5% CO2 atmosphere. The cells were sequentially
treated with oligomycin (1 lM) p-trifluoromethoxy carbonyl cya-
nide phenyl hydrazine (0.5 uM) antimycinA (1 lM) and rotenone
(1 lM). Oxygen consumption rate (OCR), leaking respiration (LR),
maximal capacity respiration (MCR) and not electron transport
chain respiration (NMR) were determined by adding 1 lM oligo-
mycin (Sigma-Aldrich, Dorset UK) (LR), carbonyl cyanide-p-tri-
fluoromethoxyphenylhydrazone (FCCP) (Sigma-Aldrich, Dorset
UK) (MCR: 2 injections of 0.5 lM and 1 lM respectively) and 1 lM
Rotenone/antimycin (Sigma-Aldrich, Dorset UK) (NMR), respec-
tively. The data were corrected by the NMR and expressed as
pmol of oxygen/min/mg of protein. The quantity of protein was
measured by Bradford assay (29).
RNAseq analysis
Total RNA was isolated from control fibroblast cells and from
patient and controls iNPC cells using the mirVanaTM miRNA
Isolation Kit (Ambion) and DNAse treated with the DNA-freeTM
DNA Removal Kit (Ambion). RNAseq libraries were prepared
using Illumina (Illumina, Inc. California, USA) TruSeq Stranded
Total RNA with Ribo-Zero Human kit and were sequenced on
an Illumina HiSeq 2500 platform using paired-end protocol. The
quality of sequencing reads was checked with FastQC (http://
www.bioinformatics.babraham.ac.uk/projects/fastqc/; date last
accessed February 20, 2018). Reads were aligned using the STAR
(v2.5.2b) aligner and the 2-pass protocol that is outlined in the
GATK documentation for calling variants from RNAseq (https://
software.broadinstitute.org/gatk/; date last accessed February
20, 2018). Number of reads mapped to genes were counted using
HTSeq-count (30). Differentially expressed genes were identified
with Bionconductor package DESeq2 (31), comparing control
fibroblast versus iNPC cells, as well as patient iNPC versus
control iNPC cells. Genes differentially expressed with a false
discovery rate (FDR) of 0.1 and a log 2 fold change 1 were
considered as differentially expressed genes. Gene set enrich-
ment analysis for gene ontology terms was performed using the
CPDB web tool (http://cpdb.molgen.mpg.de/; date last accessed
February 20, 2018).
Proteomic analysis: sample preparation
Samples (two biological replicates per condition) were solubi-
lized in 1% SDS (w/v), 50 mM Tris–Cl pH 7.8, 150 mM NaCl, sup-
plemented with protease inhibitor Complete Mini and
phosphatase inhibitor cocktail PhosSTOP (Roche, Switzerland).
The Bichinonic acid assay (BCA) (Thermo Scientific, USA) was
used to determine protein concentrations. Cysteines were re-
duced with 10 mM dithiothreitol for 30 min at 56C and alky-
lated with 30 mM iodoacetamide for 20 min at room
temperature, in the dark. Per sample, a volume corresponding
to 10 mg of protein was 10-fold diluted with ice-cold ethanol, fol-
lowed by 60 min of incubation at 40C. The sample was centri-
fuged for 30 min at 4C and 18 000g and the supernatant was
discarded. The protein pellet was resolubilized in 5 mL of 4 M
guanidinium chloride and diluted 20-fold with 50 mM ammo-
nium bicarbonate (ABC). Trypsin (Promega, USA) was added in a
ratio 1: 20 (trypsin: protein, w/w) and samples were digested at
37C for 14 h. Digestion was stopped by adding trifluoroacetic
acid to a final concentration of 1%. Digestions were quality con-
trolled by separation of 1 mg on a monolithic column according
to Burkhart et al. (32).
Nano-LC-MS/MS analysis
Per sample 0.5 mg were analyzed using an Ultimate 3000 nano
RSLC (Thermo Scientific) coupled to an Orbitrap Fusion Lumos
(Thermo Scientific, Germany). Peptides were pre-concentrated
on a 75 lm 2 cm C18 Acclaim Pepmap trapping column
(Thermo Scientific, Germering, Germany) in 0.1% TFA for 10 min
using a flow rate of 20 ml/min, followed by separation on a
75 lm 50 cm Acclaim Pepmap C18 main column using a binary
gradient (A: 0.1% formic acid, B: 84% acetonitrile, 0.1% formic
acid) ranging from 3% to 30% B in 85 min at a flow rate of
250 nl/min. Samples were analysed in data-dependant acquisi-
tion mode (DDA). MS survey scans were acquired in the Orbitrap
from 300 to 1500 m/z at a resolution of 120 000 using the polysi-
loxane ion at 371.1012 m/z as lock mass (33). For MS/MS precur-
sors were selected using the top speed option (3 s) and a
dynamic exclusion of 15 s. Peptides were selected with an isola-
tion window of 1.2 m/z and fragmented using higher-energy col-
lisional dissociation (HCD) with a normalized collision energy of
30%, and fragment ion spectra were acquired in the ion trap in
rapid mode. Automatic gain control (AGC) settings were 2  105
(MS) and 2  103 (MS/MS) ions, maximum injection times were
set to 50 ms (MS) and 300 ms (MS/MS), respectively (34,35).
Mitochondrial calciummetabolism studies
Fibroblast and iNPC cell lines were seeded (100 000 cells/dish) on
glass bottom dishes and allowed to adhere overnight. Rhod-2-
am (ThermoFisher) was used to evaluate mitochondrial Ca2þ,
respectively. Rhod-2 (8 lM) was loaded at room temperature for
30 min. Cells were washed twice with PBS and incubated in
tyrodes solution [137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, 0.2
mM Na2HPO4, 12 mm NaHCO3, 2 mM CaCl2, 10 mM Glucose, pH
7 (Sigma-Aldrich) for 15 min]. Dynamic measurements of mito-
chondrial Ca2þwere performed at room temperature with a
Nikon A1R inverted confocal microscope equipped with a 60,
1.40 NA oil objective in resonant scanning mode at 3.7 fps for 5
min. After 1 min (providing basal fluorescence) histamine (100
lM; Sigma-Aldrich) was added to evoke IP3R-dependent ER
Ca2þ release and the Ca2þ transient was monitored. Image
analysis was performed in Fiji, the background was subtracted
and Ca2þ levels were calculated as (F – F0)/F0 where F indicates
fluorescence and F0 basal fluorescence.
Autophagy detection
Control and patient fibroblasts and iNPCs were cultured on cov-
erslips and subjected to autophagy activity assays as described
in the manufacturer instructions (Autophagy Detection Kit
ab139484, Abcam, Cambridge, MA). For positive control cells
were subjected to Rapamycin for 14–16 h.
Proteomic data analysis
Data analysis for label-free quantification was performed with
the Progenesis QI from Nonlinear Dynamics (Newcastle upon
Tyne, UK). MS raw files were automatically aligned, followed by
peak picking. Only peptides with charge statesþ2,þ3 andþ4
were considered for peptide statistics, analysis of variance
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(ANOVA) and principal component analysis (PCA). Only MS/MS
spectra with ranks 1–10 were exported as peak lists with a lim-
ited fragment ion count 100. Using searchGUI (33) spectra were
searched against a target/decoy version of the human Uniprot
database (downloaded July 2015, containing 20 207 target
sequences) using X! Tandem Vengeance (2015.12.15.2).
Additionally, spectra were searched using Mascot 2.5 (Matrix
Science). Search parameters were: trypsin as enzyme with a
maximum of two missed cleavages, carbamidomethylation of
Cys set as fixed modification, oxidation of Met set as variable
modification, MS and MS/MS tolerances of 10 ppm and 0.5 Da,
respectively. PeptideShaker 1.10.3 was used to combine all
search result files and filter data at a FDR of 1% on the protein
and peptide level (34). Obtained identifications were exported
using the advanced PeptideShaker features that allow direct re-
import of the quality-controlled data into Progenesis.
Only proteins quantified with at least one unique peptide
were exported from Progenesis. Then, for each protein, the av-
erage of the normalized abundances (obtained from Progenesis)
from the biological replicate analyses was calculated to deter-
mine the ratios between the samples and control. Only proteins
which were (i) commonly quantified in all the replicates with (ii)
at least two unique peptides, (iii) an ANOVA P-value of<0.05
(Progenesis) and (iv) a 2-fold regulation between samples and
controls were considered as regulated.
A set of 85 regulated proteins were used to generate a high
confidence STRING network (http://string-db.org/) and to ana-
lyse the enrichment of Gene Ontology terms.
Supplementary Material
Supplementary Material is available at HMG online.
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